Genmab A/S ADS (GMAB) is a publicly traded Healthcare sector company. As of July 15, 2026, GMAB trades at $29.00 with a market cap of $17.68B and a P/E ratio of 0.00. GMAB moved +0.94% today. Year to date, GMAB is -6.72%; over the trailing twelve months it is +33.88%. Its 52-week range spans $17.24 to $35.43. Analyst consensus is strong buy with an average price target of $35.36. Rallies surfaces GMAB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for GMAB, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $29.00 |
| Market Cap | $17.68B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $35.43 |
| 52-Week Low | $17.24 |
| Volume | 30.81K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
9 analysts cover GMAB: 0 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.36.